CNS Pharmaceuticals Inc. has released its financial results for the second quarter of 2025, reporting a net loss of approximately $2.4 million, a slight improvement from the $2.5 million net loss in the same period of 2024. This change is attributed to declining trial costs in the Berubicin trial. Research and development expenses for the quarter increased slightly to $1.2 million from $1.1 million in the previous year, mainly due to expenditures related to preparing for a TPI 287 trial, including drug manufacturing, despite the declining trial costs for Berubicin. General and administrative expenses saw a decrease to approximately $1.2 million compared to $1.4 million in the same period of 2024, due to reductions in legal and professional expenses, travel expenses, and stock-based compensation, partially offset by increases in compensation and insurance expenses. As of June 30, 2025, CNS Pharmaceuticals had a strong cash position of approximately $12.1 million, which is expected to support operations into the second half of 2026. The company is advancing its lead program, TPI 287, towards a Phase 2 study for the treatment of glioblastoma multiforme (GBM), with plans to engage the FDA on the design of a study for the registration of TPI 287 in recurrent GBM within the year. The commencement of a Phase 2 study for TPI 287 is anticipated in the first half of 2026.